Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 5
1995 1
1999 2
2000 2
2002 1
2003 4
2004 5
2005 10
2006 23
2007 11
2008 25
2009 24
2010 28
2011 42
2012 47
2013 51
2014 85
2015 77
2016 106
2017 124
2018 135
2019 152
2020 159
2021 142
2022 154
2023 114
2024 60

Text availability

Article attribute

Article type

Publication date

Search Results

1,390 results

Results by year

Filters applied: . Clear all
Page 1
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.
White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L; CARES Investigators. White WB, et al. N Engl J Med. 2018 Mar 29;378(13):1200-1210. doi: 10.1056/NEJMoa1710895. Epub 2018 Mar 12. N Engl J Med. 2018. PMID: 29527974 Free article. Clinical Trial.
RESULTS: In total, 6190 patients underwent randomization, received febuxostat or allopurinol, and were followed for a median of 32 months (maximum, 85 months). ...CONCLUSIONS: In patients with gout and major cardiovascular coexisting conditions, febuxostat was nonin …
RESULTS: In total, 6190 patients underwent randomization, received febuxostat or allopurinol, and were followed for a median of 32 mo …
The role of febuxostat in gout.
Bardin T, Richette P. Bardin T, et al. Curr Opin Rheumatol. 2019 Mar;31(2):152-158. doi: 10.1097/BOR.0000000000000573. Curr Opin Rheumatol. 2019. PMID: 30601228 Review.
PURPOSE OF REVIEW: Concerns about the cardiovascular safety of febuxostat lead to reconsideration of the place of febuxostat in the management of gout. RECENT FINDINGS: The CARES trial is a randomized controlled trial mandated by the FDA to compare the cardiovascula …
PURPOSE OF REVIEW: Concerns about the cardiovascular safety of febuxostat lead to reconsideration of the place of febuxostat i …
Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis.
Gao L, Wang B, Pan Y, Lu Y, Cheng R. Gao L, et al. Clin Cardiol. 2021 Jul;44(7):907-916. doi: 10.1002/clc.23643. Epub 2021 May 20. Clin Cardiol. 2021. PMID: 34013998 Free PMC article. Review.
The cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout remains equivocal. ...This meta-analysis adds new evidence regarding the cardiovascular safety of febuxostat in patients. Initiation of febuxostat in patients was not as …
The cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout remains equivocal. ...This meta-analysis ad …
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, Ralston SH, Walters M, Robertson M, De Caterina R, Findlay E, Perez-Ruiz F, McMurray JJV, MacDonald TM; FAST Study Group. Mackenzie IS, et al. Lancet. 2020 Nov 28;396(10264):1745-1757. doi: 10.1016/S0140-6736(20)32234-0. Epub 2020 Nov 9. Lancet. 2020. PMID: 33181081 Free article. Clinical Trial.
BACKGROUND: Febuxostat and allopurinol are urate-lowering therapies used to treat patients with gout. Following concerns about the cardiovascular safety of febuxostat, the European Medicines Agency recommended a post-licensing study assessing the cardiovascular safe …
BACKGROUND: Febuxostat and allopurinol are urate-lowering therapies used to treat patients with gout. Following concerns about the ca …
Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, Ito S, Yamamoto T, Tomino Y, Ohno I, Shibagaki Y, Iimuro S, Imai N, Kuwabara M, Hayakawa H, Ohtsu H, Ohashi Y; FEATHER Study Investigators. Kimura K, et al. Am J Kidney Dis. 2018 Dec;72(6):798-810. doi: 10.1053/j.ajkd.2018.06.028. Epub 2018 Sep 1. Am J Kidney Dis. 2018. PMID: 30177485 Free article. Clinical Trial.
RESULTS: Of 443 patients who were randomly assigned, 219 and 222 assigned to febuxostat and placebo, respectively, were included in the analysis. ...The incidence of gouty arthritis was significantly lower (P=0.007) in the febuxostat group (0.91%) than in the placeb …
RESULTS: Of 443 patients who were randomly assigned, 219 and 222 assigned to febuxostat and placebo, respectively, were included in t …
Febuxostat for the treatment of gout.
Bridgeman MB, Chavez B. Bridgeman MB, et al. Expert Opin Pharmacother. 2015 Feb;16(3):395-8. doi: 10.1517/14656566.2015.985588. Epub 2015 Jan 5. Expert Opin Pharmacother. 2015. PMID: 25556668 Review.
AREAS COVERED: This article reviews the published literature on the pharmacologic characteristics and clinical safety and efficacy data on the use of febuxostat in the treatment of gout. A literature search of MEDLINE and MEDLINE In-Process & Other Non-Indexed Citation …
AREAS COVERED: This article reviews the published literature on the pharmacologic characteristics and clinical safety and efficacy data on t …
Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial.
Saag KG, Becker MA, White WB, Whelton A, Borer JS, Gorelick PB, Hunt B, Castillo M, Gunawardhana L; CARES Investigators. Saag KG, et al. Arthritis Rheumatol. 2022 Sep;74(9):1593-1601. doi: 10.1002/art.42160. Epub 2022 Aug 5. Arthritis Rheumatol. 2022. PMID: 35536764 Free PMC article. Clinical Trial.
OBJECTIVE: To investigate whether serum urate levels, number of gout flares, and tophi burden are related to death from cardiovascular (CV) causes after treatment with febuxostat or allopurinol in patients with gout from the Cardiovascular Safety of Febuxostat or Al …
OBJECTIVE: To investigate whether serum urate levels, number of gout flares, and tophi burden are related to death from cardiovascular (CV) …
Verinurad/Febuxostat and Nephrotoxicity.
Fernandez-Prado R, Ortiz A. Fernandez-Prado R, et al. Am J Kidney Dis. 2021 Sep;78(3):468. doi: 10.1053/j.ajkd.2021.03.029. Epub 2021 Jun 11. Am J Kidney Dis. 2021. PMID: 34126127 No abstract available.
Febuxostat and renal outcomes: post-hoc analysis of a randomized trial.
Kohagura K, Kojima S, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Hiramitsu S, Waki M, Jinnouchi H, Kakuda H, Hayashi T, Kawai N, Sugawara M, Mori H, Tsujita K, Matsui K, Hisatome I, Ohya Y, Kimura K, Saito Y, Ogawa H; Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study (FREED) investigators. Kohagura K, et al. Hypertens Res. 2023 Jun;46(6):1417-1422. doi: 10.1038/s41440-023-01198-x. Epub 2023 Feb 7. Hypertens Res. 2023. PMID: 36750608 Clinical Trial.
The relative risk of developing or worsening macroalbuminuria was 56% lower in the febuxostat group (hazard ratio, 0.44; 95% CI, 0.24-0.82; P = 0.0098). ...In patients with asymptomatic hyperuricemia without gout, febuxostat reduces the risk of development or worsen …
The relative risk of developing or worsening macroalbuminuria was 56% lower in the febuxostat group (hazard ratio, 0.44; 95% CI, 0.24 …
Febuxostat-Induced Toxic Epidermal Necrolysis.
Han P, Hu L. Han P, et al. Am J Ther. 2022 Nov-Dec 01;29(6):e710-e712. doi: 10.1097/MJT.0000000000001256. Epub 2020 Oct 1. Am J Ther. 2022. PMID: 33021532 No abstract available.
1,390 results

Searches related to "febuxostat"